SpaceX or Rocket Lab: Which Space Stock Is the Better Buy for the Next Decade?

The article favors Rocket Lab over SpaceX on valuation, citing Rocket Lab's $38B market capitalization and 48x trailing price-to-sales ratio versus SpaceX's $2T valuation and 91x P/S multiple. SpaceX's Starlink generated $4.3B of quarterly revenue, up 66% year over year, with $1.66B in operating income, but its stated $1T revenue target by 2030 is viewed as unlikely against $21B of trailing-12-month revenue. Rocket Lab's planned roughly $8B acquisition of Iridium and development of the Neutron rocket could expand its satellite-services and launch capabilities; its trailing-12-month sales reached $769M, up 1,400% over five years.

Analysis

The relevant valuation issue is not simply relative P/S: RKLB would be underwriting simultaneous execution of a heavy-lift development program and a leveraged telecom acquisition. If financed materially with stock, an $8B transaction would create substantial dilution; if debt-funded, it would shift the equity narrative from long-duration optionality to integration, refinancing, and free-cash-flow credibility. IRDM equity holders should receive the cleaner near-term catalyst through an acquisition premium, while RKLB’s multiple is vulnerable if pro forma leverage, spectrum/contract liabilities, or closing conditions exceed expectations.

A combined RKLB/IRDM could create a vertically integrated constellation-and-launch platform, but the strategic value is likely several years away: launch cost savings only matter once Neutron achieves reliable cadence, and satellite replacement cycles constrain near-term synergy capture. The more immediate second-order beneficiary is ASTS, whose valuation could gain from renewed attention to direct-to-device satellite economics without inheriting RKLB’s acquisition-financing risk. Conversely, Viasat and Globalstar face a higher competitive narrative risk if a credible alternative gains distribution partnerships or government contracts.

Consensus may be treating scale as inherently de-risking. In practice, a capital-intensive acquisition ahead of proven heavy-lift operations can reduce strategic flexibility precisely when launch delays require incremental cash. Over the next 1-3 months, the decisive datapoints are transaction consideration, committed financing, pro forma net leverage, IRDM customer-retention terms, and a Neutron schedule supported by test milestones rather than management targets. Falsify the cautious view if disclosed synergies and contracted backlog support deleveraging within 24-36 months and Neutron clears major qualification milestones on schedule.

Key Decisions for Investors

• Do not chase RKLB on the strategic narrative before definitive IRDM deal terms and financing are filed. Treat a material equity component, pro forma net leverage above roughly 3x EBITDA, or a delayed Neutron test milestone as a short/underweight trigger over the next 1-3 months.
• Buy IRDM only as a merger-arbitrage position after confirming consideration and regulatory path; size to the spread, not the standalone satellite thesis. Exit if the implied annualized spread no longer compensates for financing or antitrust/foreign-investment review risk.
• Express the relative thesis as long ASTS / short RKLB only after the transaction is definitive and RKLB financing is known. The trade targets re-rating of direct-to-device optionality versus dilution/integration risk; cover the RKLB short if Neutron reaches a successful major test milestone or disclosed financing is materially less dilutive than expected.
• For SPCX exposure, avoid assuming orbital AI is an investable earnings catalyst in the next 12-18 months. Reassess only when power, thermal-management, launch cadence, and signed external compute demand are disclosed; absent these, the concept is more likely to increase capital intensity than near-term multiple support.